Clinical Report: A Lipid Pathway in Glaucoma?

Overview

A small human donor-retina study reported reduced sphingomyelin (SM) and increased acid sphingomyelinase (ASM) in retinal ganglion cells (RGCs) from eyes with glaucoma. Ceramide aggregates were also increased, although total RGC ceramide and the measured SM-synthesizing enzymes did not differ significantly between groups. The findings are exploratory and do not establish ASM inhibition as a treatment.

Background

Glaucoma is a progressive optic neuropathy associated with RGC degeneration and optic nerve injury; intraocular pressure (IOP) is a major risk factor. The study examined whether SM metabolism, in addition to established areas of glaucoma research such as pressure and neuronal injury, is altered in human RGCs. SM is a membrane phospholipid, and ASM converts SM into ceramide. Current guideline context in the supplied material emphasizes IOP-lowering treatments and reports insufficient evidence to recommend neuroprotective agents or alternative treatments.

Data Highlights

Key Findings

• Investigators analyzed fixed and flash-frozen human donor retinal tissue from donors with and without a glaucoma diagnosis, identifying RGCs with RBPMS labeling and detecting SM with EGFP-Lysenin.
• RGC density was significantly lower in glaucoma donor retinas, and SM labeling was significantly reduced in surviving RGCs.
• Reduced SM was independently confirmed in flash-frozen retinal homogenates; the authors suggest the finding may not be explained solely by fewer surviving RGCs.
• ASM expression was significantly higher in glaucomatous RGC layers and individual RGCs, whereas NSM, SMS1, and SMS2 did not show significant changes.
• Total RGC ceramide did not differ significantly, but ceramide aggregates within RGCs were significantly more abundant in glaucoma donor eyes.
• The authors propose localized ASM-mediated SM breakdown as a possible contributor to ceramide-rich membrane platforms and pro-apoptotic signaling. They note the small donor sample, incomplete medical histories, and imbalance in causes of death, including more sepsis among glaucoma donors, as limitations.

Clinical Implications

The study provides exploratory human tissue evidence of altered ASM–SM–ceramide pathway measures in glaucoma, but it does not demonstrate that ASM inhibition is effective or safe in patients. The supplied guideline context states that evidence is insufficient to recommend neuroprotective agents or alternative treatments; established glaucoma management remains centered on IOP lowering.

Conclusion

Human donor retinas with glaucoma showed reduced RGC sphingomyelin, increased ASM expression, and more intracellular ceramide aggregates, with no significant change in total RGC ceramide or measured SM-synthesizing enzymes. These findings warrant interpretation in light of the study’s stated limitations and do not establish a clinical role for targeting ASM.

Related Resources & Content

1. Scientific Reports, 2026 -- Human glaucoma is associated with sphingomyelin depletion and acid sphingomyelinase elevation in retinal ganglion cells
2. European Glaucoma Society, 2026 -- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines
3. American Academy of Ophthalmology, 2025 -- Primary Open-Angle Glaucoma Preferred Practice Pattern
4. Acta Neuropathologica, 2016 -- Exploring Glaucoma: Impacts on the Retina and Beyond
5. Frontiers in Neurology — Tau Pathology and Microglial Changes in Glaucoma: Possible Connections to Phagocytosis-Related Damage
6. glaucoma physician — Pathology of the Outflow System
7. glaucoma physician — Ocular Blood and Aqueous Flow in Relation to Development of Open-angle Glaucoma
8. Human glaucoma is associated with sphingomyelin depletion and acid sphingomyelinase elevation in retinal ganglion cells
9. Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines
10. Primary Open-Angle Glaucoma Preferred Practice Pattern
11. Primary Open-Angle Glaucoma Preferred Practice Pattern® - Ophthalmology
12. Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial | Glaucoma | JAMA Ophthalmology | JAMA Network
13. Study Info | Ocular Hypertension Treatment Study (OHTS) | Washington University in St. Louis
14. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
15. Evaluating Primary Treatment for People with Advanced Glaucoma
16. Identifying potential key metabolic pathways and biomarkers in glaucoma: a systematic review and meta-analysis - PMC
17. Human glaucoma is associated with sphingomyelin depletion and acid sphingomyelinase elevation in retinal ganglion cells | Scientific Reports